Clinical trials: Atrial Fibrillation New Onset, active
Atrial Fibrillation
Pharmacological Intervention to Prevent NOAF After TAVR
The goal of this clinical trial is to learn if amiodarone or metoprolol works to prevent new-onset atrial fibrillation (AF) in patients who develop certain atrial arrhythmias after transcatheter aortic valve replacement (TAVR).
- Trial name
- NCT07519161
- Testing
- Metoprolol succinate, Amiodarone
- Volunteers
- 198 people
- Sponsor
- Shanghai East Hospital
Coronary Artery Bypass Grafting, Remimazolam
Remimazolam for Postoperative Atrial Fibrillation
Atrial fibrillation (AF) is the most common cardiac severe arrhythmia globally and is associated with an increased risk of mortality and morbidity, with a loss of 6.0 million disability-adjusted life-years worldwide in 2017…
- Trial name
- RePAF (NCT05891145)
- Testing
- Remimazolam, midazolam
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Yangzhou University
Critical Illness, New Onset Atrial Fibrillation
Magnesium Prophylaxis for the Prevention of New-Onset Atrial Fibrillation in Critically Ill Patients
A double-blind, multi-centre, randomized, placebo-controlled, feasibility pilot trial in the prevention of new onset atrial fibrillation of critically ill patients admitted to an ICU.
- Trial name
- ATOMIC (NCT05829317)
- Testing
- Magnesium sulfate
- Where
- 4 sites in Canada
- Volunteers
- 200 people
- Sponsor
- Dr. Stephanie Sibley
Left Bundle Branch Area Pacing, Right Ventricular Pacing
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
This is a single-center, randomized controlled study. The aim of this study is to compare the impact of left bundle branch area pacing versus traditional right ventricular pacing on the incidence of atrial fibrillation in…
- Conditions
- Left Bundle Branch Area Pacing, Right Ventricular Pacing, Atrioventricular Block, Atrial Fibrillation
- Trial name
- NCT06023784
- Testing
- left bundle branch area pacing, right ventricular pacing
- Where
- China
- Volunteers
- 530 people
- Sponsor
- Peking Union Medical College Hospital
Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke)
Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation (NVAF), Who Have Not Received Oral Anticoagulation Therapy (OAC-therapy) Prior to Inclusion
Background: Atrial fibrillation (AF) is the most common heart rhythm disorder worldwide. Globally, there are 37.5 million people with AF.
- Conditions
- Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke), Atrial Fibrillation New Onset, Non Valvular Atrial Fibrillation
- Trial name
- BIO-AF (NCT06949319)
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- Nedim Tojaga
Atrial Fibrillation New Onset, Acute Myocardial Infarction
BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction
To validate the prognostic importance of the burden of new-onset atrial fibrillation (NOAF) complicating acute myocardial infarction (AMI) in a prospectively designed hospital-based registry.
- Trial name
- BENEFIT-AMI (NCT04528511)
- Testing
- Continuous Electronic Monitor
- Where
- 5 sites in China
- Volunteers
- 774 people
- Sponsor
- Shanghai 10th People's Hospital
Atrial Fibrillation New Onset
Promoting Atrial Fibrillation Screening in Primary Care
Atrial fibrillation is the most common sustained cardiac arrhythmia in adults. Due to the asymptomatic and paroxysmal nature (randomly and shortly occurring of atrial fibrillation, and can therefore remain unnoticed) of atrial…
- Trial name
- NCT06458829
- Testing
- SEARCH-AF
- Volunteers
- 4,800 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Post Operative Atrial Fibrillation, Atrial Fibrillation, Postoperative
BoxX-NoAF Clinical Trial
Post Operative Atrial Fibrillation (POAF) is the most common complication of cardiac surgery. POAF incidence can exceed 50% depending on the patient baseline characteristics and surgery type.
- Trial name
- NCT06989775
- Testing
- Isolator® Synergy™ EnCompass® Ablation System and AtriClip® LAA Exclusion System
- Where
- 37 sites in United States, Canada
- Volunteers
- 960 people, healthy volunteers welcome
- Sponsor
- AtriCure, Inc.
Ischemic Stroke, Cryptogenic, Ischemic Stroke, Embolic
Left Atrial Strain and Cryptogenic Stroke
Cryptogenic stroke is a type of stroke in which the cause of the blood clot cannot be identified, leaving many patients without a clear treatment plan and at high risk for another stroke.
- Conditions
- Ischemic Stroke, Cryptogenic, Ischemic Stroke, Embolic, Hemorrhagic Stroke, Embolic Stroke of Undetermined Source
- Trial name
- LAS-ESUS (NCT07224178)
- Where
- United States
- Volunteers
- 900 people
- Sponsor
- University of Pittsburgh
Atrial Fibrillation (AF), Atrial Fibrillation New Onset
Clinical Validation of SMD-AFECG for Predicting New-Onset Atrial Fibrillation Within 2 Hours Using Single-Lead ECG Data
The purpose of this retrospective study is to evaluate the clinical performance of SMD-AFECG, an artificial intelligence-based medical device software that predicts the risk of atrial fibrillation occurring within 2 hours using…
- Trial name
- NCT07722078
- Volunteers
- 797 people
- Sponsor
- HUINNO Co., Ltd
Heart Failure, Atrial Fibrillation (AF)
Bachmann Bundle Pacing for Prevention of New-Onset Atrial Fibrillation in Patients With Heart Failure
This is a multi-center, prospective, single-blind, randomized controlled clinical trial to evaluate the efficacy and safety of Bachmann bundle pacing (BBP) in preventing new-onset atrial fibrillation (AF) in patients with chronic…
- Conditions
- Heart Failure, Atrial Fibrillation (AF), Cardiac Insufficiency
- Trial name
- NCT07547449
- Testing
- Bachmann Bundle Pacing, Right Atrial Appendage Pacing
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Fu Wai Hospital, Beijing, China
Supraventricular Arrhythmia, Septic Shock
Rate, Rhythm or Risk Control for New-onset Supraventricular Arrhythmia During Septic Shock: a Randomized Controlled Trial
New-onset supraventricular arrhythmia (NOSVA) is reported in 40 % of patients with septic shock and is associated with hemodynamic alterations and mortality.
- Trial name
- CAFS (NCT04844801)
- Testing
- Risk control strategy, Heart-Rate control strategy:, Rhythm control strategy:
- Where
- France
- Volunteers
- 240 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Atrial Fibrillation New Onset, New Onset Atrial Fibrillation
Tracking Atrial Fibrillation After Intensive Care Admission
Atrial fibrillation (AF) is a heart problem that causes an irregular heartbeat. It can cause the heart to beat more rapidly and reduce the heart's ability to pump blood around the body efficiently, causing heart failure.
- Conditions
- Atrial Fibrillation New Onset, New Onset Atrial Fibrillation, Atrial Fibrillation
- Trial name
- TrAFFIC (NCT05229211)
- Testing
- Cardiac monitoring
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- University of Oxford
Atrial Fibrillation New Onset
Short Term Anti-aRrhythmic Therapy for Post-Operative AF in Cardiac Surgery Patients Pilot Trial
The START-POAF pilot study is a prospective, open-label two-arm, randomized controlled trial with blinded assessment of outcomes (PROBE).
- Trial name
- START-POAF (NCT05841056)
- Testing
- Amiodarone Hydrochloride 200 MG
- Where
- 2 sites in Canada
- Volunteers
- 400 people
- Sponsor
- Population Health Research Institute
New-onset Atrial Fibrillation (NOAF)
The Basel CardioInsightTM - 3D Mapping Study
This study is to describe the exact location of NOAF-maintaining foci and rotors after cardiac surgery identified by mapping using the non-invasive phase mapping with CardioInsightTM - 3D Mapping technology (CardioInsightTM…
- Trial name
- BigMap (NCT04964765)
- Testing
- Mapping, Computed tomography scan
- Where
- 2 sites in Austria, Switzerland
- Volunteers
- 157 people
- Sponsor
- University Hospital, Basel, Switzerland
Atrial Fibrillation
Long-term Recurrence Rates of Atrial Fibrillation Following New-onset Atrial Fibrillation During ICU Admission
The Primary Objective of the study is to establish the One-year recurrence rates of atrial fibrillation (AF) following new-onset atrial fibrillation during intensive care unit (ICU) admission.
- Trial name
- NCT05151523
- Volunteers
- 100 people
- Sponsor
- Katia Orvin
Coronary Artery Disease, Stroke
Effects of Left Atrial Appendage Resection and Marshall Ligament Amputation on Clinical Outcome in Patients Undergoing Off-pump Coronary Artery Bypass
Surgical occlusion of the left atrial appendage (LAAO) is sometimes performed during the cardiac surgery to reduce long-term risk of stroke.A previous study found that LAAO may be associated with increased risk of postoperative…
- Conditions
- Coronary Artery Disease, Stroke, Atrial Fibrillation
- Trial name
- NCT04220047
- Testing
- Left Atrial Appendage Resection and Marshall Ligament Amputation
- Where
- China
- Volunteers
- 400 people
- Sponsor
- China National Center for Cardiovascular Diseases
Postoperative Atrial Fibrillation
The Effect of Ligament of Marshall Excision During Minimally Invasive Cardiac Surgery-Coronary Artery Bypass Grafting (MICS-CABG) on the Prevention of Postoperative New-Onset Atrial Fibrillation: A Multicenter, Prospective, Randomized, Triple-Blinded Study
After heart bypass surgery, many patients develop a heart rhythm problem called postoperative atrial fibrillation, or POAF for short. This issue happens to 20%-40% of all bypass patients.
- Trial name
- NCT07755072
- Testing
- MICS-CABG combined with excision of the Ligament of Marshall
- Where
- China
- Volunteers
- 628 people
- Sponsor
- Peking University Third Hospital
New Onset, Atrial Fibrillation
Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery
Recently, dexmedetomidine has been suggested as an alternative agent for sedation in tachyarrhythmias due to its antiarrhythmic properties through decreased catecholamine release, prolonged refractory period, and increased vagal…
- Trial name
- NCT07482540
- Testing
- Dexmedetomidine, Saline
- Volunteers
- 140 people
- Sponsor
- Ain Shams University
Embolic Stroke of Undetermined Source, Atrial Fibrillation New Onset
EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined Source
Atrial fibrillation (AF) is the most common heart rhythm problem in the adult population. There is a five-fold increase in stroke risk in patients with AF.
- Trial name
- EMPA-ESUS (NCT06715449)
- Testing
- Empagliflozin 10 MG
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- University of East Anglia